PROSPECTS FOR THE USE OF INHALATION ANTIBACTERIAL DRUGS IN RESPIRATORY INFECTIONS ( REVIEW)
Keywords:
antibacterial drug resistance, inhalation antibacterial drugs, ower respiratory tract infections, pyocyanic infectionAbstract
The need to find ways to improve the effectiveness of antibacterial therapy is due to the dramatic escalation of resistance to antibacterial drugs (ABD), while the growth rate of resistance to antibacterial drugs is outpacing the dynamics of the development of new drugs. The article presents up-to-date data on existing inhaled ABPs, allowing to evaluate their effectiveness and safety.
References
Abdellatif S., Trifi A., Daly F. et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomized trial. Ann. intensity. care. 2016; 6:26. DOI: 10.1186/s13613-016-0127-7.
Allcock S., Young EH, Holmes M. et al. Antimicrobial resistance in human populations: challenges and opportunities. Glob. Health epidemiol. Genom. 2017; 2:e4. DOI: 10.1017/gheg.2017.4.
Aslam B., Wang W., Arshad M.I. et al. Antibiotic resistance: a rundown of a global crisis. Infect. drug resistance. 2018; 11: 1645–1658. DOI: 10.2147/IDR.S173867.
Becattini S., Taur Y., Pamer EG Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 2016; 22(6): 458–478. DOI: 10.1016/j.molmed.2016.04.003.
Brown RL, Sequeira RP, Clarke TB The microbiota protects against respiratory infection via GM-CSF signaling. Nat. commun. 2017; 8:1512. DOI: 10.1038/s41467-017-01803-x.
Barker AF, O'Donnell AE, Flume P. et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomized double-blind, placebo-controlled phase 3 trials. Lancet Respirator. Med. 2014; 2(9): 738–749. DOI: 10.1016/S2213-2600(14)70165-1.
Barker AF, Couch L., Fiel SB et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med.2000; 162(2, Pt 1): 481–485. DOI: 10.1164/ajrccm.162.2.9910086.
Blasi F., Page C., Rossolini GM et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117:190-197. DOI: 10.1016/j.rmed.2016.06.015.
Castro-Sánchez E., Moore LSP, Husson F., Holmes AH What are the factors driving antimicrobial resistance? Perspectives from a public event in London, England. BMC Infect. Dis. 2016; 16:465. DOI: 10.1186/s12879-016-1810-x.
Chokshi A., Sifri Z., Cennimo D., Horng H. Global contributors to antibiotic resistance. J Glob. Infect. Dis. 2019; 11(1):36–42. DOI: 10.4103/jgid.jgid_110_18.
Cuthbertson L., Rogers GB, Walker AW et al. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J. 2016; 10:1081–1091. DOI: 10.1038/ismej.2015.198.
Clarke TB Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect. Immun. 2014; 82(11): 4596–4606. DOI: 10.1128/IAI.02212-14.
Carcas AJ, Garcia-Satue JL, Zapater P., Frias-Iniesta J. Tobramycin penetration into the epithelial lining fluid of patients with pneumonia. Clin. Pharmacol. Ther. 1999; 65 (3): 245–250. DOI: 10.1016/S0009-9236(99)70103-7.
Cipolla D., Blanchard J., Gonda I. Development of liposomal ciprofloxacin to treat lung infections. pharmaceuticals. 2016; 8(1):6. DOI: 10.3390/pharmaceutics8010006.
Deshmukh HS, Liu Y., Menkiti OR et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat. Med. 2014; 20:524–530. DOI: 10.1038/nm.3542.
Dhand R. The rationale and evidence for the use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J. Aerosol. Med. Pulm. DrugDeliv.2018; 31(3): 121–138. DOI: 10.1089/jamp.2017.1415.
Drobnic ME, Suñé P., Montoro JB et al Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. 2005; 39(1): 39–44. DOI: 10.1345/aph.1E099.
Elborn JS, Flume PA, Cohen F. et al. Safety and efficacy of continued levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J. Cyst. Fibros. 2016; 15(5): 634–640. DOI:10.1016/j.jcf.2016.01.005.
Elborn JS, Geller DE, Conrad D. et al. A phase 3, openlabel, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycininhalation solution in stable cystic fibrosis patients. J. Cyst. Fibros. 2015; 14(4): 507–514. DOI: 10.1016/j.jcf.2014.12.013.
Francis JK, Higgins E. Permanent peripheral neuropathy: a case report on a rare but serious debilitating side-effect of fluoroquinolone administration. J. Investig. Med. High Impact Case Rep. 2014; 2 (3): 2324709614545225. DOI: 10.1177/232470 9614545225.
Foreman A., Psaltis AJ, Tan LW et al. Characterization of bacterial and fungal biofilms in chronic rhinosinusitis. Am. J. Rhinol. Allergy. 2009; 23(6): 556–561. DOI: 10.2500/ajra.2009.23.3413.
Feeley TW, Du Moulin GC, Hedley-Whyte J. et al. Aerosol polymyxin and pneumonia in seriously ill patients. N. Engl. J. Med. 1975; 293:471–475. DOI: 10.1056/NEJM197509042931003.
Gauguet S., D'Ortona S., Ahnger-Pier K. et al. Intestinal microbiota of mice influences resistance to Staphylococcus aureus pneumonia. Infect. Immun. 2015; 83(10): 4003–4014. DOI:10.1128/IAI.00037-15.
Heta S., Robo I. The side effects of the most commonly used group of antibiotics in periodontal treatments. Med. sci. (Basel). 2018; 6 (1): 6. DOI: 10.3390/medsci6010006.
Haworth CS, Bilton D., Chalmers JD et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa(ORBIT-3 and ORBIT-4): two phase 3, randomized controlled trials. Lancet Respirator. Med. 2019; 7(3):213–226. DOI: 10.1016/S2213-2600(18)30427-2
Hansen C., Skov M. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis. Ther. Adv. Respir. Dis. 2015; 9(1):16–21. DOI: 10.1177/1753465814561624.
Ichinohe T., Pang IK, Kumamoto Y. et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. sci. USA. 2011; 108(13): 5354–5359. DOI: 10.1073/pnas.1019378108.
Khosravi A., Yanez A., Price J. et al. Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe. 2014; 15(3): 374–381. DOI: 10.1016/j.chom.2014.02.006.
Kim YK, Lee JH, Lee HK et al. Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. J. Thorac. Dis. 2017; 9(3): 555–567. DOI: 10.21037/jtd.2017.02.61.
Li J., Xie S., Ahmed S. et al. Antimicrobial activity and resistance: influencing factors. front. Pharmacol. 2017; 8: 364. DOI: 10.3389/fphar.2017.00364.
Langdon A., Crook N., Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016; 8:39. DOI: 10.1186/s13073-016-0294-z.
Lu Q., Girardi C., Zhang M. et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. intensity. Care Med. 2010; 36:1147–1155. DOI:10.1007/s00134-010-1879-4.
Laska IF, Crichton ML, Shoemark A., Chalmers JD The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir. Med. 2019; 7(10): 855–869. DOI: 10.1016/S2213-2600(19)30185-7.
McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr. Nephrol.2017; 32: 2015–2025. DOI: 10.1007/s00467-016-3533-z.
Ma TKW, Chow KM, Choy ASM et al. Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients. Clin. Kidney. J. 2014; 7(6): 507–512. DOI: 10.1093/ckj/sfu098.
Michalak K., Sobolewska-Wlodarczyk A., Wlodarczyk M. et al. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications. oxide. Med. cell. Longev. 2017; 2017: 8023935. DOI: 10.1155/2017/8023935.
Murray MP, Govan JRW, Doherty CJ et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2011; 183(4):491–499. DOI: 10.1164/rccm.201005-0756OC.
Marchese A., Debbia EA, Tonoli E. et al. In vitro activity ofthiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy. J Chemotherapy. 2002; 14(6): 554–561. DOI: 10.1179/joc.2002. 14.6.554.
Macchi A., Ardito F., Marchese A. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intra-muscular/aerosol) therapy of upper respiratory tract infectionseven when sustained by bacterial biofilms. J Chemother. 2006; 18(5): 507–513. DOI: 10.1179/joc.2006.18.5.507.
Macchi A., Castelnuovo P. Aerosol antibiotic therapy in children with chronic upper airway infections: a potential alternative to surgery. Int. J. Immunopathol. Pharmacol. 2009; 22(2):303–310. DOI: 10.1177/039463200902200207.
Mogayzel PJ Jr, Naureckas ET, Robinson KA et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann. Am. Thorac. soc. 2014;11(10): 1640–1650. DOI: 10.1513/AnnalsATS.201404-166OC.
Niederman MS, Chastre J., Corkery K. et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012; 38:263–271. DOI: 10.1007/s00134-011-2420-0.
Nurbaeti SN, Olivier JC, Adier C. et al. Active mediated transport of chloramphenicol and thiamphenicol in a Calu-3 lung epithelial cell model. J Pharm. sci. 2018; 107(4): 1178–1184. DOI: 10.1016/j.xphs.2017.11.021.
Polverino E., Goeminne PC, McDonnell MJ et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 2017; 50 (3): 1700629. DOI: 10.1183/13993003.00629-2017.
Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin. Pharmacokinet. 2011; 50(10): 637–664. DOI: 10.2165/11594090-000000000-00000.
Serra A., Schito GC, Nicoletti G. et al. A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route). Int. J. Immunopathol. Pharmacol. 2007; 20(3): 607–617. DOI: 10.1177/039463200702000319.
Singer AC, Shaw H., Rhodes V., Hart A. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. front. microbiol. 2016; 7:1728. DOI: 10.3389/fmicb.2016.01728.
Schuijt TJ, Lankelma JM, Scicluna BP et al. The gut microbiota plays a protective role in the host defense against pneumococcal pneumonia. gut. 2016; 65(4): 575–583. DOI:10.1136/gutjnl-2015-309728.
Schuster A., Haliburn C., Döring G. et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomized study. Thorax. 2013; 68(4): 344–350. DOI: 10.1136/thoraxjnl-2012-202059.
Spellberg B., Blaser M., Guidos RJ et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 2011; 52 (Suppl. 5): S397–428. DOI: 10.1093/cid/cir153.
Sylvester JT, Shimoda LA, Aaronson PI, Ward JPT Hypoxic pulmonary vasoconstriction. physiol. Rev. 2012; 92(1): 367–520. DOI: 10.1152/physrev.00041.2010.
Teo SM, Mok D., Pham K. et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015; 17(5):704–715. DOI: 10.1016/j.chom.2015.03.008.
Telfer SJ Fluoroquinolone antibiotics and type 2 diabetes mellitus. Med. hypotheses. 2014; 83(3): 263–269. DOI: 10.1016/j.mehy.2014.05.013.
Vendrell M., Muñoz G., de Gracia J. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. Open Respirator. Med. J. 2015; 9:30–36. DOI: 10.2174/1874306401509010030.
Wenzler E., Fraidenburg DR, Scardina T., Danziger LH Inhaled antibiotics for gram-negative respiratory infections. Clin. microbiol. Rev. 2016; 29(3): 581–632. DOI: 10.1128/CMR.00101-15.
7. Wiest DB, Cochran JB, Tecklenburg FW Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess. J. Pediatr. Pharmacol. Ther. 2012; 17(2): 182–188. DOI:10.5863/1551-6776-17.2.182.
Wilson R., Welte T., Polverino E. et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomized study. Eur. Respir. J. 2013; 41(5): 1107–1115. DOI: 10.1183/09031936.00071312.
Yang JW, Fan LC, Lu HW et al. Efficacy and safety of longterm inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis. Clin. Respir. J. 2016; 10(6):731–739. DOI: 10.1111/crj.12278.
Zimlichman E ., Henderson D., Tamir O . et al. Health care associated infections. a meta-analysis of costs and financial impact on the US health care system. JAMA Intern. Med. 2013;173 (22): 2039–2046. DOI: 10.1001/jamainternmed.2013.9763.
Zhang L., Huang Y., Zhou Y. et al. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. Antimicrob. Agents Chemother. 2013; 57(8): 3659–3666. DOI: 10.1128/AAC.00670-13.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
